Identification of Connective Tissue Disease autoantibodies and a novel autoantibody anti-Annexin A11 in patients with “idiopathic” interstitial lung disease

the UK-BILD Collaboration

Research output: Contribution to journalArticlepeer-review

Abstract

Background
Autoantibodies are a hallmark feature of Connective Tissue Diseases (CTD). Their presence in patients with idiopathic interstitial lung disease (ILD) may suggest covert CTD. We aimed to determine the prevalence of CTD autoantibodies in patients diagnosed with idiopathic ILD.

Methods
499 patient sera were analysed: 251 idiopathic pulmonary fibrosis (IPF), 206 idiopathic non-specific interstitial pneumonia (iNSIP) and 42 cryptogenic organising pneumonia (COP). Autoantibody status was determined by immunoprecipitation.

Results
2.4% of IPF sera had a CTD-autoantibody compared to 10.2% of iNSIP and 7.3% of COP. 45% of autoantibodies were anti-synthetases. A novel autoantibody targeting an unknown 56 kDa protein was found in seven IPF patients (2.8%) and two NSIP (1%) patients. This was characterised as anti-annexin A11.

Conclusion
Specific guidance on autoantibody testing and interpretation in patients with ILD could improve diagnostic accuracy. Further work is required to determine the clinical significance of anti-annexin A11.
Original languageEnglish
JournalClinical Immunology
Publication statusAccepted/In press - 1 Apr 2024

Keywords

  • Autoantibody
  • Connective tissue disease
  • Diagnostic assay
  • Interstitial lung disease
  • Myositis
  • Systemic Sclerosis

Fingerprint

Dive into the research topics of 'Identification of Connective Tissue Disease autoantibodies and a novel autoantibody anti-Annexin A11 in patients with “idiopathic” interstitial lung disease'. Together they form a unique fingerprint.

Cite this